MedTrace Logo

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Conditions

Interventions

DRUG

ladiratuzumab vedotin

Intravenous (into the vein; IV) infusion

DRUG

pembrolizumab

200mg given by IV on Day 1 of each 21-day cycle

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-09
Primary Completion
2023-11-28
Completion
2023-11-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Italy
  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04032704 on ClinicalTrials.gov